source
- TRexBio raises $117 million in IPO as Retension secures $45 million Nasdaq debut for hypertension therapyTRexBio completed its initial public offering on Thursday, pricing the shares at a level that generated about $116.7 million in gross proceeds. The funding will support the company’s development of…
- FDA week: HHS launches vaccine injury study, midterms may reshape oversight committees, and patent thickets threaten genericsThe Department of Health and Human Services announced a new agency‑wide effort to examine and address injuries that may be linked to vaccines. The initiative will coordinate research across FDA and…